WO1998018470A1 - Composition destinee au traitement de l'asthme et contenant de la loratadine et un decongestionnant - Google Patents

Composition destinee au traitement de l'asthme et contenant de la loratadine et un decongestionnant Download PDF

Info

Publication number
WO1998018470A1
WO1998018470A1 PCT/US1997/019158 US9719158W WO9818470A1 WO 1998018470 A1 WO1998018470 A1 WO 1998018470A1 US 9719158 W US9719158 W US 9719158W WO 9818470 A1 WO9818470 A1 WO 9818470A1
Authority
WO
WIPO (PCT)
Prior art keywords
loratadine
pseudoephedrine
asthma
milligrams
decongestant
Prior art date
Application number
PCT/US1997/019158
Other languages
English (en)
Inventor
Alan G. Harris
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to EP97912874A priority Critical patent/EP0941091A1/fr
Priority to IL12966297A priority patent/IL129662A0/xx
Priority to NZ335078A priority patent/NZ335078A/xx
Priority to AU49953/97A priority patent/AU731756B2/en
Priority to JP10520579A priority patent/JP2000505104A/ja
Priority to CA002268546A priority patent/CA2268546A1/fr
Priority to SK545-99A priority patent/SK54599A3/sk
Priority to BR9712705-1A priority patent/BR9712705A/pt
Publication of WO1998018470A1 publication Critical patent/WO1998018470A1/fr
Priority to NO992062A priority patent/NO992062D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Definitions

  • the invention relates to methods for relieving symptoms of allergic diseases, and more particularly to 5 relieving bronchial asthma symptoms.
  • Asthma is considered to be a very serious chronic allergic disorder, and is typically characterized by airway hyperresponsiveness, recurrent airflow obstruction and symptoms of cough, wheezing and 0 breathlessness . It is one of the most common chronic diseases of childhood, perhaps affecting as many as ten percent of children. Asthma is economically very significant, as it causes considerable time loss from jobs and school, is one of the most common reasons for 5 visits to the physician and is responsible for many admissions to emergency treatment facilities and hospitals. Asthma is also responsible for significant mortality, particularly when not properly treated. It is generally accepted that asthma is 0 characterized by chronic airway inflammation, varying degrees of airway obstruction which is usually reversible, and increases in airway responsiveness to a variety of stimuli. Muscle spasm, airway edema, abnormal mucous production and an inflammatory cell 5 filtrate can often be observed during an acute exacerbation, frequently referred to by sufferers as "an asthma attack.”
  • Airway edema and bronchospasm usually can be successfully treated with bronchodilators, such as epinephrine and the ⁇ 2 -agonists albuterol (also called “salbutamol” ) , metaproterenol , pirbuterol, terbutaline and salmeterol .
  • Airway narrowing can usually be blocked by administering systemic corticosteroids, such as prednisone, or inhaled anti-inflammatory drugs such as beclomethasone dipropionate, flunisolide, triamcinolone acetonide, cromolyn sodium and nedocromil sodium.
  • the /3 2 -agonists are used as daily maintenance medications and as "rescue" medications, when they are administered as needed when exacerbated symptoms are experienced.
  • Systemic corticosteroids are given therapeutically, usually in large doses, for treatment of status asthmaticus, while the corticosteroids are prophylactic and are typically administered for the more severe cases in regular, spaced doses regardless of current symptoms. Action of these treatments results in relief from cough, wheezing and the feeling of breathlessness, plus a reduction in airway narrowing which can easily be quantified by measuring improvements in the patient's forced expiratory volume (FEV) or peak expiratory flow (PEF) rate values; the determination and significance of these parameters are discussed at pages 584-599 of R. Berkow, Ed., The Merck Manual of Diagnosis and Therapy, Fifteenth Edition, Merck Sharp & Dohme Research Laboratories, Rahway, New
  • Antihistamines are weak bronchodilators, and newer agents, many of which are not available in the United States, have some anti- inflammatory properties. They are not as effective as other medications available for the treatment of asthma, and thus do not have a role in routine asthma management.. They are mentioned here, however, to counteract the statements found in many package inserts that antihistamines should not be used in patients with asthma. Their use in patients with upper airway allergies is not contraindicated if the patient has asthma and they may have a beneficial effect on the asthma as well.
  • Terfenadine has also been studied, as reported by. A. Taytard et al . , "Treatment of Bronchial Asthma with Terfenadine; a Randomised Controlled Trial," British Journal of Clinical Pharmacology, Vol. 24, pages 743- 746 (1987); P. Rafferty et al . , "Terfenadine, a Potent Histamine H j ⁇ -Receptor Antagonist in the Treatment of Grass Pollen Sensitive Asthma," British Journal of
  • Decongestant drugs are often used to treat allergic rhinitis. The most significant of these are sympathomimetic amines having Q ⁇ -adrenergic stimulating activity. Among the more widely used orally delivered agents are phenylpropanolamine , ephedrine and pseudoephedrine . Decongestants have long been used in combination with antihistamines for treating allergic and other forms of rhinitis, and some of the publications discussed above relating to cetirizine and terfenadine studies indicate that patients in the antihistamine clinical studies were allowed to use pseudoephedrine for additional relief of symptoms. However, there is no unexpected benefit attributed to this use. SUMMARY OF THE INVENTION
  • the invention encompasses a method for improving pulmonary function of a patient suffering from asthma, comprising administering to the patient the customary rhinitis treatment-effective amounts of loratadine and a decongestant .
  • a preferred decongestant is pseudoephedrine
  • a presently preferred daily treatment for obtaining the desired results of the invention includes 10 milligrams of loratadine and one of: 240 milligrams of pseudoephedrine, administered in a suitable extended release formulation for 24 -hour effectiveness; or two daily doses of 5 milligrams of loratadine and 120 milligrams of pseudoephedrine, administered in an extended release formulation for 12 -hour effectiveness; or in up to four divided doses of immediate release formulations during 24 hours, totalling 10 milligrams of loratadine and 240 milligrams of pseudoephedrine.
  • the individual drugs can be administered separately or in a combination dosage form.
  • Fig. 1 is a graphical representation of morning PEF data obtained in the clinical test of the example.
  • Fig. 2 is a graphical representation of evening PEF data obtained in the clinical test of the example
  • Fig. 3 is a graphical representation of FEV data obtained in the clinical test of the example.
  • a reference herein to "customary rhinitis- effective treatment amounts" of a drug is intended to indicate those doses which are approved by any relevant regulatory agencies, such as the United States Food and Drug Administration, for use of the drug to treat symptoms of allergic rhinitis.
  • References herein to "improving pulmonary function” are meant to include a facilitation of gas exchange processes in the lungs, particularly as shown clinically by improvements in measured FEV and/or PEF values for a patient; such improvements will usually be accompanied by a reduction in the patient's perception of shortness of breath.
  • Loratadine chemically ethyl-4- (8-chloro-5 , 6- dihydro-HH-benzo [5, 6] cyclohepta [1, 2 -b] pyridin-11- ylidene) -1-piperidinecarboxylate with an empirical formula C 22 H 23 C1N 2 0 2 and a molecular weight of 382.89, is a very widely used nonsedating antihistamine drug with a superb safety profile.
  • the active drug and its preparation are described in United States Patent 4,282,233 to Vilani.
  • the drug may also conveniently be prepared according to the process described in United States Patent 4,731,447 to Schumacher et al .
  • loratadine may be administered in any of several dosage forms, including, without limitation, tablets, capsules, syrups or by injection; as with most drugs, oral administration in the form of a tablet or capsule will be preferred for patient convenience.
  • An effective antihistaminic dose of loratadine ranges from about 5 to about 40 milligrams daily. Due to the systemic half-lives of loratadine and its active metabolites, the daily dose may be given once each 24 hours or divided into 2, 3, or 4 preferably equal portions for administration to match the frequency of decongestant drug dosing.
  • a typical daily dose of loratadine for relief of the symptoms of allergic rhinitis is 10 milligrams. Schering Corporation of Kenilworth, New Jersey markets a 10 milligram loratadine tablet under the brand CLARITIN ® .
  • Useful decongestant drugs include topical decongestants and systemic decongestants.
  • Topical decongestants are typically administered in the form of drops or aerosols such as nasal sprays, and contain such drugs as oxymetazoline, phenylephrine, naphazoline, xylometazoline, ephedrine, epinephrine, methylhexaneamine, tetrahydrozoline and xylometazoline. Topical decongestants are not preferred for long-term therapy, due to the eventual appearance of rhinitis medicamentosa which can usually be treated only by discontinuing administration of the drug.
  • Suitable systemic decongestant drug compounds for the practice of the invention include the sympathomimetic amines phenylpropanolamine, ephedrine, pseudoephedrine and phenylephrine, a reference herein to the drug specifically including pharmaceutically acceptable salts thereof, where necessary.
  • the most widely used of these is pseudoephedrine, due to its favorable balance of efficacy and safety; typically, the water-soluble hydrochloride, sulfate or other salts are used to formulate products.
  • Pseudoephedrine sulfate is chemically [S- (R* , R*) ] -a-
  • pseudoephedrine salts may be administered in any of several dosage forms, including, without limitation, tablets, capsules, syrups or by injection; as with most drugs, oral administration in the form of a tablet or capsule will be preferred for patient convenience .
  • pseudoephedrine sulfate or hydrochloride will be administered to adults in daily doses of 120 to 360 milligrams, and to children in daily doses of 60 to 180 milligrams, for the alleviation of congestion from allergic rhinitis.
  • pseudoephedrine is considerably shorter than that of loratadine.
  • immediate release formulations individual doses of 60 milligrams are usually administered to an adult patient four times in each 24 -hour period.
  • extended release solid formulations are known in the art, for example to make 120 milligrams of the drug effective over a 12-hour period, and 240 milligrams effective for a full 24 hours.
  • loratadine and decongestant be dosed together.
  • loratadine can be administered once daily, while the decongestant drug is administered more frequently to maintain a therapeutic systemic drug level. Even when the drugs are dosed together, it is not necessary that they are present in the same formulation or dosage form.
  • Formulations which combine doses of antihistaminic drugs and decongestant drugs are well known in the art .
  • loratadine these include a formulation containing 5 milligrams of loratadine and 60 milligrams of pseudoephedrine sulfate for immediate release from a tablet coating, together with 60 milligrams of pseudoephedrine which is released at a controlled rate from an erodible tablet matrix, for providing effectiveness over a 12 -hour period; a useful product is commercially available in the United States from Schering Corporation of Kenilworth, New Jersey under the brand CLARITIN-D ® 12 HOUR.
  • Another formulation incorporates 10 milligrams of loratadine for immediate release from a tablet coating together with 240 milligrams of pseudoephedrine which is released at a controlled rate from an erodible tablet matrix, for providing effectiveness over a 2 -hour period; this technique is described in United States Patent 5,314,697 to Kwan et al . and a useful product is available in the United States from Schering
  • Fig. 1 shows results from morning measurements of PEF rates for patients receiving loratadine and pseudoephedrine sulfate (solid line) and placebo (broken line) .
  • the ordinate is the mean change of PEF rate from baseline values, expressed in liters per minute.
  • Fig. 2 is a similar representation of results from an evening measurement of PEF rates for the patients, the groups being identified as above. The similar clear, statistically significant improvement during the study is a result of the drug combination administration .
  • Fig. 3 is a representation of further study results, as generated by measurements of FEV in the first second ("FEV. ').
  • the ordinate shows mean change from baseline FEV 1 values, expressed in liters.
  • Data from patients receiving loratadine and pseudoephedrine sulfate are identified by the solid bar, while data from patients receiving only placebo are represented by the open bar.
  • the very clear, statistically significant improvement in pulmonary function during the study is due to the drug combination administration .

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un procédé permettant une amélioration des fonctions pulmonaires d'un patient atteint d'asthme. Ce procédé consiste à administrer au patient les doses de loratadine habituellement utilisées pour le traitement de la rhinite en association avec un décongestionnant tel que la pseudoéphédrine.
PCT/US1997/019158 1996-10-31 1997-10-29 Composition destinee au traitement de l'asthme et contenant de la loratadine et un decongestionnant WO1998018470A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP97912874A EP0941091A1 (fr) 1996-10-31 1997-10-29 Composition destinee au traitement de l'asthme et contenant de la loratadine et un decongestionnant
IL12966297A IL129662A0 (en) 1996-10-31 1997-10-29 Composition for the treatment of asthma containing loratadine and a decongestant
NZ335078A NZ335078A (en) 1996-10-31 1997-10-29 Composition, for the treatment of asthma, containing loratadine and a decongestant
AU49953/97A AU731756B2 (en) 1996-10-31 1997-10-29 Composition, for the treatment of asthma, containing loratadine and a decongestant
JP10520579A JP2000505104A (ja) 1996-10-31 1997-10-29 喘息の治療のためのロラタジンおよび充血除去剤を含む組成物
CA002268546A CA2268546A1 (fr) 1996-10-31 1997-10-29 Composition destinee au traitement de l'asthme et contenant de la loratadine et un decongestionnant
SK545-99A SK54599A3 (en) 1996-10-31 1997-10-29 Composition for the treatment of asthma, containing loratadine and a decongestant
BR9712705-1A BR9712705A (pt) 1996-10-31 1997-10-29 Composição para o tratamento da asma, contendo loratadina e um descongestionante
NO992062A NO992062D0 (no) 1996-10-31 1999-04-29 Preparat for behandling av astma, inneholdende loratadin og et dekongestionsmiddel

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73966996A 1996-10-31 1996-10-31
US08/739,669 1996-10-31

Publications (1)

Publication Number Publication Date
WO1998018470A1 true WO1998018470A1 (fr) 1998-05-07

Family

ID=24973307

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/019158 WO1998018470A1 (fr) 1996-10-31 1997-10-29 Composition destinee au traitement de l'asthme et contenant de la loratadine et un decongestionnant

Country Status (21)

Country Link
EP (1) EP0941091A1 (fr)
JP (1) JP2000505104A (fr)
KR (1) KR20000052922A (fr)
CN (1) CN1235545A (fr)
AR (1) AR008908A1 (fr)
AU (1) AU731756B2 (fr)
BR (1) BR9712705A (fr)
CA (1) CA2268546A1 (fr)
CO (1) CO4910128A1 (fr)
CZ (1) CZ150999A3 (fr)
HU (1) HUP9904075A3 (fr)
ID (1) ID23431A (fr)
IL (1) IL129662A0 (fr)
NO (1) NO992062D0 (fr)
NZ (1) NZ335078A (fr)
PE (1) PE11399A1 (fr)
PL (1) PL333056A1 (fr)
SK (1) SK54599A3 (fr)
TR (1) TR199901003T2 (fr)
WO (1) WO1998018470A1 (fr)
ZA (1) ZA979731B (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062516A1 (fr) * 1998-06-01 1999-12-09 Schering Corporation Sirop a antihistamines stabilise contenant un stabilisant acide aminopolycarboxylique
WO2000015226A1 (fr) * 1998-09-10 2000-03-23 Schering Corporation Anti-histamines traitant la sinusite ou l'otite moyenne non infectieuse
WO2000050015A1 (fr) * 1999-02-23 2000-08-31 Yuhan Corporation Compositions de capsules pharmaceutiques contenant de la loratadine et de la pseudoephedrine
EP1032392A1 (fr) * 1997-10-29 2000-09-06 J-Med Pharmaceuticals, Inc. Schema posologique de traitement de la rhinite a base d'antihistaminique et de decongestionnant
WO2000057880A1 (fr) * 1999-03-29 2000-10-05 Schering Corporation Procedes et compositions pour traiter des troubles allergiques et troubles associes au moyen de descarboethoxyloratadine fluoree
WO2001078782A1 (fr) * 2000-04-14 2001-10-25 J-Med Pharmaceuticals, Inc. Formulations antihistaminiques/decongestionnantes a dose unique
WO2001089527A2 (fr) * 2000-05-24 2001-11-29 Schering Corporation Compositions solides et liquides stables
WO2003000264A1 (fr) * 2001-06-20 2003-01-03 Schering Corporation Antihistaminiques pour le traitement de congestion nasale et d'obstruction nasale
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
KR100505899B1 (ko) * 1999-02-23 2005-08-01 주식회사유한양행 로라타딘과 슈도에페드린을 함유한 캅셀제 조성물
WO2006135254A1 (fr) 2005-06-17 2006-12-21 Aft Pharmaceuticals Limited Nouvelle composition pharmaceutique et son utilisation dans un procédé de traitement de patients atteints de congestion des muqueuses des voies respiratoires supérieures
KR100687806B1 (ko) * 1998-07-28 2007-02-28 니콕스 에스. 에이. 특정약의 질산에스테르 및 질산염
US8956662B2 (en) * 2006-06-01 2015-02-17 Msd Consumer Care, Inc. Phenylephrine pharmaceutical formulations and compositions for colonic absorption

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045676A2 (fr) * 1999-12-20 2001-06-28 Schering Corporation Composition de dose orale a liberation prolongee
SK287684B6 (sk) * 1999-12-20 2011-06-06 Schering Corporation Pevná orálna farmaceutická dávková forma s predĺženým uvoľňovaním
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
KR101540191B1 (ko) * 2014-02-24 2015-07-28 성균관대학교산학협력단 로라타딘을 포함하는 항염증용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1110397A (en) * 1964-10-02 1968-04-18 Mead Johnson & Co Ephedrine composition
EP0396404A1 (fr) * 1989-05-03 1990-11-07 Schering Corporation Composition pharmaceutique contenant de la loratadine, de l'ibuprofène et de la pseudoéphédrine
WO1994009761A1 (fr) * 1992-10-23 1994-05-11 Schering Corporation Composition stable de dose administree oralement et a liberation prolongee
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
WO1996020708A1 (fr) * 1994-12-30 1996-07-11 Sepracor, Inc. Procedes et composition de traitement de la rhinite allergique et d'autres troubles au moyen de descarboethoxyloratadine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1110397A (en) * 1964-10-02 1968-04-18 Mead Johnson & Co Ephedrine composition
EP0396404A1 (fr) * 1989-05-03 1990-11-07 Schering Corporation Composition pharmaceutique contenant de la loratadine, de l'ibuprofène et de la pseudoéphédrine
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
WO1994009761A1 (fr) * 1992-10-23 1994-05-11 Schering Corporation Composition stable de dose administree oralement et a liberation prolongee
WO1996020708A1 (fr) * 1994-12-30 1996-07-11 Sepracor, Inc. Procedes et composition de traitement de la rhinite allergique et d'autres troubles au moyen de descarboethoxyloratadine

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1032392A1 (fr) * 1997-10-29 2000-09-06 J-Med Pharmaceuticals, Inc. Schema posologique de traitement de la rhinite a base d'antihistaminique et de decongestionnant
EP1032392A4 (fr) * 1997-10-29 2001-05-09 J Med Pharmaceuticals Inc Schema posologique de traitement de la rhinite a base d'antihistaminique et de decongestionnant
US6939550B2 (en) 1998-06-01 2005-09-06 Schering Corporation Stabilized antihistamine syrup
WO1999062516A1 (fr) * 1998-06-01 1999-12-09 Schering Corporation Sirop a antihistamines stabilise contenant un stabilisant acide aminopolycarboxylique
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
JP2002516860A (ja) * 1998-06-01 2002-06-11 シェーリング コーポレイション 安定化剤としてアミノポリカルボン酸を含有する安定化抗ヒスタミンシロップ
US6514520B2 (en) 1998-06-01 2003-02-04 Schering Corporation Stabilized antihistamine syrup
KR100687806B1 (ko) * 1998-07-28 2007-02-28 니콕스 에스. 에이. 특정약의 질산에스테르 및 질산염
WO2000015226A1 (fr) * 1998-09-10 2000-03-23 Schering Corporation Anti-histamines traitant la sinusite ou l'otite moyenne non infectieuse
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
WO2000050015A1 (fr) * 1999-02-23 2000-08-31 Yuhan Corporation Compositions de capsules pharmaceutiques contenant de la loratadine et de la pseudoephedrine
KR100505899B1 (ko) * 1999-02-23 2005-08-01 주식회사유한양행 로라타딘과 슈도에페드린을 함유한 캅셀제 조성물
WO2000057880A1 (fr) * 1999-03-29 2000-10-05 Schering Corporation Procedes et compositions pour traiter des troubles allergiques et troubles associes au moyen de descarboethoxyloratadine fluoree
WO2001078782A1 (fr) * 2000-04-14 2001-10-25 J-Med Pharmaceuticals, Inc. Formulations antihistaminiques/decongestionnantes a dose unique
AU2000242484B2 (en) * 2000-04-14 2006-02-09 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
WO2001089527A2 (fr) * 2000-05-24 2001-11-29 Schering Corporation Compositions solides et liquides stables
WO2001089527A3 (fr) * 2000-05-25 2003-10-16 Schering Corp Compositions solides et liquides stables
WO2003000264A1 (fr) * 2001-06-20 2003-01-03 Schering Corporation Antihistaminiques pour le traitement de congestion nasale et d'obstruction nasale
WO2006135254A1 (fr) 2005-06-17 2006-12-21 Aft Pharmaceuticals Limited Nouvelle composition pharmaceutique et son utilisation dans un procédé de traitement de patients atteints de congestion des muqueuses des voies respiratoires supérieures
EP1896022A1 (fr) * 2005-06-17 2008-03-12 AFT Pharmaceuticals Limited Nouvelle composition pharmaceutique et son utilisation dans un procédé de traitement de patients atteints de congestion des muqueuses des voies respiratoires supérieures
EP1896022A4 (fr) * 2005-06-17 2008-08-06 Aft Pharmaceuticals Ltd Nouvelle composition pharmaceutique et son utilisation dans un procédé de traitement de patients atteints de congestion des muqueuses des voies respiratoires supérieures
US8603523B2 (en) 2005-06-17 2013-12-10 Aft Pharmaceuticals Limited Pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion
US8956662B2 (en) * 2006-06-01 2015-02-17 Msd Consumer Care, Inc. Phenylephrine pharmaceutical formulations and compositions for colonic absorption

Also Published As

Publication number Publication date
AR008908A1 (es) 2000-02-23
NO992062L (no) 1999-04-29
JP2000505104A (ja) 2000-04-25
NZ335078A (en) 2000-10-27
EP0941091A1 (fr) 1999-09-15
PE11399A1 (es) 1999-02-09
CZ150999A3 (cs) 1999-10-13
NO992062D0 (no) 1999-04-29
KR20000052922A (ko) 2000-08-25
AU4995397A (en) 1998-05-22
HUP9904075A2 (hu) 2000-05-28
PL333056A1 (en) 1999-11-08
SK54599A3 (en) 2000-08-14
AU731756B2 (en) 2001-04-05
IL129662A0 (en) 2000-02-29
CO4910128A1 (es) 2000-04-24
HUP9904075A3 (en) 2002-02-28
CA2268546A1 (fr) 1998-05-07
TR199901003T2 (xx) 1999-07-21
ZA979731B (en) 1998-04-29
ID23431A (id) 2000-04-20
BR9712705A (pt) 1999-10-26
CN1235545A (zh) 1999-11-17

Similar Documents

Publication Publication Date Title
AU731756B2 (en) Composition, for the treatment of asthma, containing loratadine and a decongestant
Van As et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate
Aaronson Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma
KR101841442B1 (ko) 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
ZA200500152B (en) Use of reboxetine for the treatment of hot flashes
Bousquet et al. A 12‐week, placebo‐controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis
Georgitis et al. Ipratropium bromide nasal spray in non‐allergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life
Kilfeather et al. Improved delivery of ipratropium bromide/fenoterol from Respimat® Soft MistTM Inhaler in patients with COPD
US20030236275A1 (en) Treatment methods of nasal congestion and nasal obstruction
von Berg et al. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat® Soft Mist™ Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma
Davies et al. Efficacy and tolerability comparison of ebastine 10 and 20mg with loratadine 10mg: a double-blind, randomised study in patients with perennial allergic rhinitis
US5376672A (en) Method for treating tension type headaches or headaches associated with drugs or their withdrawal
CA2420532A1 (fr) Utilisation d'une combinaison de salmeterol et de propionate de fluticasone
McAllen et al. Intranasal flunisolide, placebo and beclomethasone dipropionate in perennial rhinitis
Mattson et al. Preventive effect of ketotifen, a new antiallergic agent, on histamine‐induced bronchoconstriction in asthmatics
Kaiser et al. Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis
Ishizuka et al. Gender and age risks for hoarseness and dysphonia with use of a dry powder fluticasone propionate inhaler in asthma.
Corren et al. Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions
MXPA99003936A (en) Composition, for the treatment of asthma, containing loratadine and a decongestant
EP2121021A2 (fr) Procédés pour traiter une congestion nasale
EP1569650B1 (fr) Utilisation de levocetirizine pour le traitement de la rhinite allergique persistante
Frew et al. Effects of 4-week treatment with low-dose budesonide (100 μg BID) from a novel inhaler AirmaxTM and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma
WO2008085392A1 (fr) Méthodes de traitement d'une congestion nasale chez des patients souffrant d'une insuffisance hépatique
McDonald et al. Comparison of oral bambuterol and terbutaline in elderly patients with chronic reversible airflow obstruction
White et al. Comparative effects of fexofenadine and montelukast on allergen-induced wheal and flare

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97199404.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CZ EE GE HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 335078

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2268546

Country of ref document: CA

Ref document number: 2268546

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 54599

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/003936

Country of ref document: MX

Ref document number: PV1999-1509

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1019997003790

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1999/01003

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1997912874

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997912874

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1999-1509

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997003790

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019997003790

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997912874

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: PV1999-1509

Country of ref document: CZ